Daniel Markowitz Analyst Performance

Vice President at Evercore ISI

Daniel Markowitz is a stock analyst at Evercore ISI focused in the medical sector, covering 8 publicly traded companies. Over the past year, Daniel Markowitz has issued 14 stock ratings, including strong buy, buy, and hold recommendations. While full access to Daniel Markowitz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Daniel Markowitz's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 14 Last 0 Years
Buy Recommendations: 92.31% 12 Buy Ratings
Companies Covered: 8 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	7.7%	1 ratings
Buy	84.6%	11 ratings
Hold	7.7%	1 ratings
Sell	0.0%	0 ratings

Out of 13 total stock ratings issued by Daniel Markowitz at Evercore ISI, the majority (84.6%) have been Buy recommendations, followed by 7.7% Strong Buy and 7.7% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	75.0% of companies on NASDAQ	6 companies
NYSE	25.0% of companies on NYSE	2 companies

Daniel Markowitz, an analyst at Evercore ISI, currently covers 8 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 7 companies	87.5%
	Computer and Technology 1 company	12.5%

Daniel Markowitz of Evercore ISI specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 3 companies	37.5%
MED/DENTAL - SUPP 1 company	12.5%
MEDICAL INFO SYS 1 company	12.5%
ELEC COMP - SEMIC 1 company	12.5%
MED INSTRUMENTS 1 company	12.5%
MEDICAL SERVICES 1 company	12.5%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
WST West Pharmaceutical Services	10/7/2025	Set Price Target	$269.32	$350.00
RGEN Repligen	10/7/2025	Boost Price Target	$144.44	$175.00	Outperform
GH Guardant Health	10/7/2025	Boost Price Target	$62.55	$68.00	Outperform
INSP Inspire Medical Systems	10/7/2025	Lower Price Target	$76.85	$125.00	Outperform
TECH Bio-Techne	10/7/2025	Boost Price Target	$59.50	$72.00	Outperform
RGEN Repligen	9/22/2025	Upgrade	$122.30	$155.00	Outperform
RMBS Rambus	9/16/2025	Boost Price Target	$98.22	$114.00	Outperform
TMDX TransMedics Group	9/16/2025	Initiated Coverage	$114.29	$155.00	Outperform
INSP Inspire Medical Systems	9/2/2025	Initiated Coverage	$93.86	$150.00	Outperform
NTRA Natera	7/28/2025	Upgrade	$138.90	$170.00	Strong-Buy
WST West Pharmaceutical Services	7/25/2025	Boost Price Target	$262.83	$350.00	Outperform
TECH Bio-Techne	3/18/2025	Initiated Coverage	$62.58	$75.00	Outperform
RGEN Repligen	3/18/2025	Initiated Coverage	$152.81	$155.00	In-Line
WST West Pharmaceutical Services	3/18/2025	Initiated Coverage	$231.60	$275.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.